精神分裂症急慢性期外周细胞因子及炎症蛋白改变模式的系统综述与网络荟萃分析
结果显示IL-1β、IL-1RA、sIL-2R、IL-6、IL-8、IL-10、TNF-α和C反应蛋白在急性和慢性期均持续升高;IL-2和IFN-γ仅在急性期显著升高,而IL-4、IL-12和IFN-γ在慢性期显著降低。作者提出持续升高的促炎蛋白可能为特质标志物,急性期叠加的免疫活性蛋白可能为状态标志物。
要点
- IL-1β、IL-1RA、sIL-2R、IL-6、IL-8、IL-10、TNF-α和CRP在精神分裂症急性和慢性期均持续高于健康对照。
- IL-2和IFN-γ仅在急性期显著升高,IL-4、IL-12和IFN-γ在慢性期显著降低。
- 持续升高的促炎蛋白可能为特质标志物,急性期叠加的免疫活性可能为状态标志物。
核心结论
- 精神分裂症谱系障碍患者在整个病程中存在基线水平的炎症蛋白改变,表现为促炎蛋白持续升高,可能为特质标志物。
- 急性精神病性发作期可能叠加免疫活性,表现为推测的状态标志物浓度升高。
研究设计与样本
- 系统综述与网络荟萃分析,检索PubMed、PsycINFO、EMBASE、CINAHL和Cochrane对照试验中心注册库从建库至2022年3月31日的文献。
- 纳入报告精神分裂症谱系障碍患者与健康对照外周炎症蛋白浓度的观察性或实验性研究,要求成人患者且有急性或慢性期指标。
主要发现
- IL-1β、IL-1RA、sIL-2R、IL-6、IL-8、IL-10、TNF-α和C反应蛋白在急性和慢性精神分裂症谱系障碍患者中均持续高于健康对照。
- IL-2和IFN-γ在急性精神分裂症谱系障碍中显著升高。
- IL-4、IL-12和IFN-γ在慢性精神分裂症谱系障碍中显著降低。
- 敏感性和荟萃回归分析显示研究质量及多数方法学、人口学和诊断因素对大多数炎症标志物的结果无显著影响,但 assay source(对IL-2和IL-8)、assay validity(对IL-1β)、研究质量(对TGF-β1)、年龄(对IFN-γ、IL-4和IL-12)、性别(对IFN-γ和IL-12)、吸烟(对IL-4)、BMI(对IL-4)、诊断组成(对IL-1β、IL-2、IL-6和TNF-α)、未用药病例(对IL-4和IL-1RA)、病程(对IL-4)、症状严重程度(对IL-4)和亚组组成(对IL-4)存在特定例外。
关键数值与推荐
- 纳入标准:观察性或实验性设计;成人精神分裂症谱系障碍患者且有急性或慢性期指标;可比较的无精神疾病健康对照;测量细胞因子、相关炎症标志物或C反应蛋白的外周蛋白浓度。
- 排除标准:未测量血液中细胞因子蛋白或相关生物标志物的研究;未以结果或补充结果报告数据的文章被排除(未联系作者);未检索灰色文献和未发表研究。
临床怎么用
- 结果提示外周炎症蛋白可能作为精神分裂症谱系障碍的潜在生物标志物,但需进一步研究确定外周改变是否反映中枢神经系统。
- 该研究为理解临床相关炎症生物标志物未来用于精神分裂症谱系障碍的诊断和预后提供了切入点。
局限性
- 整个队列的年龄、男女数量和族裔的描述数据不可用。
- 未检索灰色文献和未发表研究,未联系作者获取未报告数据。
- 部分炎症标志物的结果受方法学、人口学和诊断因素影响,存在特定例外。
- 外周改变是否反映中枢神经系统尚不明确。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Immune system dysfunction is considered to play an aetiological role in schizophrenia spectrum disorders, with substantial alterations in the concentrations of specific peripheral inflammatory proteins, such as cytokines. However, there are inconsistencies in the literature over which inflammatory proteins are altered throughout the course of illness. Through conducting a systematic review and network meta-analysis, this study aimed to investigate the patterns of alteration that peripheral inflammatory proteins undergo in both acute and chronic stages of schizophrenia spectrum disorders, relative to a healthy control population. METHODS: In this systematic review and meta-analysis, we searched PubMed, PsycINFO, EMBASE, CINAHL, and the Cochrane Central Register of Controlled Trials from inception to March 31, 2022, for published studies reporting peripheral inflammatory protein concentrations in cases of people with schizophrenia-spectrum disorders and healthy controls. Inclusion criteria were: (1) observational or experimental design; (2) a population consisting of adults diagnosed with schizophrenia-spectrum disorders with a specified indicator of acute or chronic stage of illness; (3) a comparable healthy control population without mental illness; (4) a study outcome measuring the peripheral protein concentration of a cytokine, associated inflammatory marker, or C-reactive protein. We excluded studies that did not measure cytokine proteins or associated biomarkers in blood. Mean and SDs of inflammatory marker concentrations were extracted directly from full-text publshed articles; articles that did not report data as results or supplementary results were excluded (ie, authors were not contacted) and grey literature and unpublished studies were not sought. Pairwise and network meta-analyses were done to measure the standardised mean difference in peripheral protein concentrations between three groups: individuals with acute schizophrenia-spectrum disorder, individuals with chronic schizophrenia-spectrum disorder, and healthy controls. This protocol was registered on PROSPERO, CRD42022320305. FINDINGS: Of 13 617 records identified in the database searches, 4492 duplicates were removed, 9125 were screened for eligibility, 8560 were excluded after title and abstract screening, and three were excluded due to limited access to the full-text article. 324 full-text articles were then excluded due to inappropriate outcomes, mixed or undefined schizophrenia cohorts, or duplicate study populations, five were removed due to concerns over data integrity, and 215 studies were included in the meta-analysis. 24 921 participants were included, with 13 952 adult cases of schizophrenia-spectrum disorder and 10 969 adult healthy controls (descriptive data for the entire cohort were not available for age, numbers of males and females, and ethnicity). Concentration of interleukin (IL)-1β, IL-1 receptor antagonist (IL-1RA), soluble interleukin-2 receptor (sIL-2R), IL-6, IL-8, IL-10, tumour necrosis factor (TNF)-α, and C-reactive protein were consistently elevated in both individuals with acute schizophrenia-spectrum disorder and chronic schizophrenia-spectrum disorder, relative to healthy controls. IL-2 and interferon (IFN)-γ were significantly elevated in acute schizophrenia-spectrum disorder, while IL-4, IL-12, and IFN-γ were significantly decreased in chronic schizophrenia-spectrum disorder. Sensitivity and meta-regression analyses revealed that study quality and a majority of the evaluated methodological, demographic, and diagnostic factors had no significant impact on the observed results for most of the inflammatory markers. Specific exceptions to this included: methodological factors of assay source (for IL-2 and IL-8), assay validity (for IL-1β), and study quality (for transforming growth factor-β1); demographic factors of age (for IFN-γ, IL-4, and IL-12), sex (for IFN-γ and IL-12), smoking (for IL-4), and BMI (for IL-4); and diagnostic factors including diagnostic composition of schizophrenia-spectrum cohort (for IL-1β IL-2, IL-6, and TNF-α), antipsychotic-free cases (for IL-4 and IL-1RA), illness duration (for IL-4), symptom severity (for IL-4), and subgroup composition (for IL-4). INTERPRETATION: Results suggest that people with schizophrenia-spectrum disorders have a baseline level of inflammatory protein alteration throughout the illness, as reflected by consistently elevated pro-inflammatory proteins, hypothesised here as trait markers (eg, IL-6), while those with acute psychotic illness might have superimposed immune activity with increased concentrations of hypothesised state markers (eg, IFN-γ). Further research is required to determine whether these peripheral alterations are reflected within the central nervous system. This research facilitates an entry point in understanding how clinically relevant inflammatory biomarkers might one day be useful to the diagnosis and prognostication of schizophrenia-spectrum disorders. FUNDING: None.
引用
- Halstead S, Siskind D, Amft M, et al. Alteration patterns of peripheral concentrations of cytokines and associated inflammatory proteins in acute and chronic stages of schizophrenia: a systematic review and network meta-analysis. Lancet Psychiatry. 2023. PMID: 36863384. doi:10.1016/S2215-0366(23)00025-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。